Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Meletios- Athanasios DimopoulosAlbert OrtiolHareth NahiJesús San F MiguelNizar J BahlisSaad Z UsmaniNeil RabinRobert Z OrlowskiKenshi SuzukiTorben PlesnerSung Soo YoonDina Ben YehudaPaul Gerard RichardsonHartmut GoldschmidtDonna ReeceTahamtan AhmadiXiang QinWendy Garvin MayoXue GaiJodi CareyRobin CarsonPhillipe MoreauPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
D-Rd significantly extended OS versus Rd alone in patients with RRMM. To our knowledge, for the first time, our findings, together with the OS benefit observed with daratumumab plus bortezomib and dexamethasone in the phase III CASTOR trial, demonstrate OS improvement with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02076009 [POLLUX]).